RACHELLE DOODY to United States Food and Drug Administration
This is a "connection" page, showing publications RACHELLE DOODY has written about United States Food and Drug Administration.
Connection Strength
0.923
-
Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. J Prev Alzheimers Dis. 2021; 8(4):393-395.
Score: 0.694
-
Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment? J Prev Alzheimers Dis. 2023; 10(3):344-345.
Score: 0.199
-
Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
Score: 0.022
-
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32.
Score: 0.008